WIRB-Copernicus Group announced that it has acquired Alliance Biosciences.
WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services for clinical research, announced that it has acquired Alliance Biosciences. Alliance Biosciences was the leading biosafety and biosecurity consulting firm in the United States and will join WCG’s biosafety division – WCG Biosafety™ – to manage the entire continuum of biosafety oversight, helping to ensure that research involving potentially hazardous agents and vectors complies with the appropriate safety and regulatory requirements from laboratory design and drug discovery through clinical testing and therapeutic application. WCG Biosafety manages more than 200 Institutional Biosafety Committees (IBCs) and has evaluated more than 140 gene transfer clinical and recombinant DNA pre-clinical research protocols to date.
Read the full release here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.